Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Feb-24 8:19 PM View:  | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 20-Feb-24 | Sale | 9,014 | $0.68 | $6,129.52 | (3%) 274.04K to 265.02K | |
| 22-Feb-24 8:17 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 20-Feb-24 | Sale | 7,606 | $0.68 | $5,172.08 | (3%) 244.28K to 236.67K | |
| 22-Feb-24 8:16 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 20-Feb-24 | Sale | 20,033 | $0.68 | $13,622.40 | (2%) 900.33K to 880.3K | |
| 20-Nov-23 10:00 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 17-Nov-23 | Sale | 19,877 | $0.49 | $9,739.73 | (2%) 920.21K to 900.33K | |
| 20-Nov-23 10:00 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 17-Nov-23 | Sale | 9,646 | $0.49 | $4,726.54 | (3%) 283.69K to 274.04K | |
| 20-Nov-23 10:00 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 17-Nov-23 | Sale | 7,179 | $0.49 | $3,517.71 | (3%) 250.96K to 243.78K | |
| 20-Sep-23 8:09 PM View: | Myriam Curet Director | Nektar Therapeutics (NKTR) | 18-Sep-23 | Sale | 4,359 | $0.69 | $3,007.71 | (14%) 31.78K to 27.42K | |
| 20-Sep-23 8:06 PM View: | Ajer Jeffrey Robert Director | Nektar Therapeutics (NKTR) | 18-Sep-23 | Sale | 4,359 | $0.69 | $3,007.71 | (11%) 38.51K to 34.15K | |
| 17-Aug-23 8:06 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-Aug-23 | Sale | 19,998 | $0.78 | $15,598.40 | (2%) 940.21K to 920.21K | |
| 17-Aug-23 8:08 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-Aug-23 | Sale | 9,703 | $0.78 | $7,568.34 | (3%) 293.39K to 283.69K | |
| 17-Aug-23 8:07 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 16-Aug-23 | Sale | 7,221 | $0.78 | $5,632.38 | (3%) 258.18K to 250.96K | |
| 15-Jun-23 6:26 PM View: | Whitfield Roy A Director | Nektar Therapeutics (NKTR) | 14-Jun-23 | Sale | 30,000 | $0.57 | $17,100.00 | (9%) 317.75K to 287.75K | |
| 17-May-23 8:29 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-May-23 | Sale | 9,791 | $0.72 | $7,049.52 | (3%) 303.18K to 293.39K | |
| 17-May-23 8:28 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 16-May-23 | Sale | 7,543 | $0.72 | $5,430.96 | (3%) 265.22K to 257.68K | |
| 17-May-23 8:27 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-May-23 | Sale | 20,361 | $0.72 | $14,659.90 | (2%) 960.57K to 940.21K | |
| 17-Feb-23 8:58 PM View: | Thomsen Jillian B. Chief Financial Officer | Nektar Therapeutics (NKTR) | 16-Feb-23 | Sale | 10,267 | $3.00 | $30,801.00 | (3%) 323.76K to 313.5K | |
| 17-Feb-23 8:57 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-Feb-23 | Sale | 19,635 | $3.00 | $58,905.00 | (2%) 980.2K to 960.57K | |
| 17-Feb-23 9:00 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-Feb-23 | Sale | 10,484 | $3.00 | $31,452.00 | (3%) 313.66K to 303.18K | |
| 17-Feb-23 8:59 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 16-Feb-23 | Sale | 8,275 | $3.00 | $24,825.00 | (3%) 273.5K to 265.22K | |
| 18-Nov-22 6:05 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-Nov-22 | Sale | 13,460 | $3.57 | $48,052.20 | (4%) 327.12K to 313.66K | |
| 18-Nov-22 6:04 PM View: | Wilson Mark Andrew Chief Legal Officer | Nektar Therapeutics (NKTR) | 16-Nov-22 | Sale | 8,690 | $3.57 | $31,023.30 | (3%) 281.19K to 272.5K | |
| 18-Nov-22 6:03 PM View: | Thomsen Jillian B. Chief Financial Officer | Nektar Therapeutics (NKTR) | 16-Nov-22 | Sale | 11,095 | $3.57 | $39,609.10 | (3%) 334.86K to 323.76K | |
| 18-Nov-22 6:02 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-Nov-22 | Sale | 38,014 | $3.57 | $135,710.00 | (4%) 1.02M to 980.2K | |
| 26-Sep-22 7:32 PM View: | Myriam Curet Director | Nektar Therapeutics (NKTR) | 23-Sep-22 | Sale | 4,198 | $3.16 | $13,265.70 | (12%) 35.98K to 31.78K | |
| 26-Sep-22 7:25 PM View: | Ajer Jeffrey Robert Director | Nektar Therapeutics (NKTR) | 23-Sep-22 | Sale | 4,198 | $3.16 | $13,265.70 | (10%) 42.71K to 38.51K | |
| 20-Sep-23 8:08 PM View: | Chess Robert Chairman of the Board Director | Nektar Therapeutics (NKTR) | 22-Sep-22 | Sale | 10,200 | $0.67 | $6,834.00 | (4%) 289.17K to 278.97K | |
| 26-Sep-22 7:23 PM View: | Chess Robert Chairman of the Board Director | Nektar Therapeutics (NKTR) | 22-Sep-22 | Sale | 5,100 | $3.19 | $16,269.00 | (2%) 294.27K to 289.17K | |
| 20-Sep-22 8:41 PM View: | Ajer Jeffrey Robert Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 31% 32.51K to 42.71K | |
| 20-Sep-22 8:48 PM View: | Greer R Scott Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 3% 293.37K to 303.57K | |
| 20-Sep-22 8:45 PM View: | Chess Robert Chairman of the Board Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 4% 284.07K to 294.27K | |
| 20-Sep-22 8:43 PM View: | Brainard Diana Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 56% 18.36K to 28.56K | |
| 20-Sep-22 8:47 PM View: | Eastham Karin Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 78% 13.03K to 23.23K | |
| 20-Sep-22 8:46 PM View: | Myriam Curet Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 40% 25.77K to 35.98K | |
| 20-Sep-22 8:49 PM View: | Whitfield Roy A Director | Nektar Therapeutics (NKTR) | 16-Sep-22 | Grant | 10,200 | -- | -- | 3% 307.55K to 317.75K | |
| 14-Sep-22 6:01 PM View: | Eastham Karin Director | Nektar Therapeutics (NKTR) | 13-Sep-22 | Sale | 21,267 | $3.61 | $76,773.90 | (62%) 34.3K to 13.03K | |
| 19-Aug-22 6:27 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 18-Aug-22 | Sale | 73,716 | $4.65 | $342,779.00 | (18%) 400.84K to 327.12K | |
| 17-Aug-22 7:39 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-Aug-22 | Sale | 13,759 | $4.76 | $65,492.80 | (1%) 1.03M to 1.02M | |
| 17-Aug-22 7:41 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-Aug-22 | Sale | 10,560 | $4.76 | $50,265.60 | (3%) 411.4K to 400.84K | |
| 17-Aug-22 7:40 PM View: | Wilson Mark Andrew SVP & General Counsel | Nektar Therapeutics (NKTR) | 16-Aug-22 | Sale | 3,189 | $4.76 | $15,179.60 | (1%) 284.38K to 281.19K | |
| 17-Aug-22 7:40 PM View: | Thomsen Jillian B. SVP & Chief Accounting Officer | Nektar Therapeutics (NKTR) | 16-Aug-22 | Sale | 2,006 | $4.76 | $9,548.56 | (< 1%) 336.87K to 334.86K | |
| 17-Aug-22 7:41 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 15-Aug-22 | Grant | 135,000 | -- | -- | 49% 276.4K to 411.4K | |
| 17-Aug-22 7:40 PM View: | Wilson Mark Andrew SVP & General Counsel | Nektar Therapeutics (NKTR) | 15-Aug-22 | Grant | 165,938 | -- | -- | 140% 118.44K to 284.38K | |
| 17-Aug-22 7:40 PM View: | Thomsen Jillian B. SVP & Chief Accounting Officer | Nektar Therapeutics (NKTR) | 15-Aug-22 | Grant | 165,938 | -- | -- | 97% 170.93K to 336.87K | |
| 17-Aug-22 7:39 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 15-Aug-22 | Grant | 410,625 | -- | -- | 66% 621.36K to 1.03M | |
| 17-May-22 9:35 PM View: | Robin Howard W President & CEO Director | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 36,529 | $3.95 | $144,290.00 | (6%) 657.88K to 621.35K | |
| 17-May-22 9:40 PM View: | Zalevsky Jonathan Chief R&D Officer | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 21,673 | $3.95 | $85,608.40 | (7%) 298.07K to 276.4K | |
| 17-May-22 9:32 PM View: | Labrucherie Gil M SVP, COO & CFO | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 17,448 | $3.95 | $68,919.60 | (5%) 330.35K to 312.9K | |
| 17-May-22 9:38 PM View: | Wilson Mark Andrew SVP & General Counsel | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 3,136 | $3.95 | $12,387.20 | (3%) 121.08K to 117.94K | |
| 17-May-22 9:33 PM View: | Northcott John SVP & Chief Commercial Officer | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 4,592 | $3.95 | $18,138.40 | (2%) 227.8K to 223.21K | |
| 17-May-22 9:36 PM View: | Thomsen Jillian B. SVP & Chief Accounting Officer | Nektar Therapeutics (NKTR) | 16-May-22 | Sale | 5,841 | $3.95 | $23,072.00 | (3%) 176.27K to 170.43K |
